Angiogenesis: Molecular mechanisms of activation, promotion and maintenance

Journal of B.U.ON.

Volumn 12, Issue SUPPL. 1, 2007, Pages

  Bikfalvi, Andreas ^a,b,c  

^a INSERM   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Angiogenesis; Development; Pathology

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PEGAPTANIB; PLACENTAL GROWTH FACTOR; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; CONFERENCE PAPER; DIABETIC RETINOPATHY; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; LYMPHANGIOGENESIS; MOLECULAR MECHANICS; MOLECULAR MIMICRY; PROTEIN EXPRESSION; RECEPTOR BINDING; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; TUMOR CELL; TUMOR VASCULARIZATION; UVEA MELANOMA;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; CHRONIC DISEASE; HUMANS; INFLAMMATION; ISCHEMIA; LYMPHANGIOGENESIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RETINAL NECROSIS SYNDROME, ACUTE; SIGNAL TRANSDUCTION;

EID: 36749009634     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 826-835.
2. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002; 23: 576-582.
3. Adams PH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 467-478.
4. Cao L, Jiao X, Zuzga DS et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 2004; 36: 827-835.
5. Autiero M, De Smet F, Claes F, Carmeliet P. Role of neural guidance signals in blood vessel navigation. Cardiovasc Res 2005; 65: 629-638.
6. Insight: Angiogenesis. Nature 2005; 438: 889-1050.
7. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005; 218: 1-14.
8. Berra E, Ginouves A, Pouyssegur J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep 2006; 7: 41-45.
9. Drogat B, Auguste P, Nguyen DT et al. IRE1 Signaling Is Essential for Ischemia-Induced Vascular Endothelial Growth Factor-A Expression and Contributes to Angiogenesis and Tumor Growth In vivo. Cancer Res 2007; 67: 6700-6707.
10. Kalas W, Yu JL, Milsom C et al. Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res 2005; 65: 8878-8886.
11. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005; 94: 209-231.
12. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 (Suppl 3): 4-10.
13. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-1370.
14. Suchting S, Bicknell R, Eichmann A. Neuronal clues to vascular guidance. Exp Cell Res 2005 Dec 2; [Epub ahead of print].
15. Lu X, Le Noble F, Yuan L et al. The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature 2004; 432: 179-186.
16. Thurston G. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003; 4: 61-68.
17. Hoffmann J, Feng Y, vom Hagen F et al. Endothelial/pericyte interactions. Circ Res 2005; 97: 512-523.
18. Nisato RE, Hosseini G, Sirrenberg C et al. Dissecting the role of matrix metalloproteinases (MMP) and integrin α(v)β3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and α(v)β3 are critical. Cancer Res 2005; 65: 9377-9387.
19. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115: 849-860.
20. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004; 64: 207-238.
21. Taverna D, Crowley D, Connolly M, Bronson RT, Hynes RO. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 2005; 65: 10324-10329.
22. Stupack DG, Cheresh DA. A Bit-role for integrins in apoptosis. Nat Cell Biol 2004; 6: 388-389.
23. Hong YK, Shin JW, Detmar M. Development of the lymphatic vascular system: a mystery unravels. Dev Dyn 2004; 231: 462-473.
24. Oliver G, Alitalo K. The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol 2005; 21: 457-483.
25. Shin JW, Min M, Larrieu-Lahargue F et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell 2006; 17: 576-584.
26. Kubo H, Cao R, Brakenhielm E et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A 2002; 99: 8868-8873.
27. Chang LK, Garcia-Cardena G, Farnebo F et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A 2004; 101: 11658-11663.
28. Hirakawa S, Kodama S, Kunstfeld R et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201: 1089-1099.
29. Tammela T, Saaristo A, Lohela M et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005; 105: 4642-4648.
30. Bjorndahl M, Cao R, Nissen LJ et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 15593-15598.
31. Cao R, Bjorndahl MA, Gallego MI et al. Hepatocyte growth factor is a novel lymphangiogenic factor with an indirect mechamism of action. Blood 2006 Jan 19; [Epub ahead of print].
32. Petrova TV, Makinen T, Makela TP et al. Free in PMC lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002; 21: 4593-4599.
33. Hirakawa S, Hong YK, Harvey N et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003; 162: 575-586.
34. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
35. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
36. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
37. Auguste P, Lemiere S, Larrieu-Lahargue F, Bikfalvi A. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 2005; 54: 53-61.
38. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3: 411-421.
39. Blouw B, Song H and Tihan T et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4: 133-146.
40. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
41. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, J Clin Invest 2003; 11: 1287-1295.
42. Erber R, Thumher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18: 338-340.
43. Bello L, Carrabba G, Giussani C et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001; 61: 7501-7506.
44. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003; 17: 1159-1161.
45. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5: 13-17.
46. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
47. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5: 436-446.
48. Lin J, Lalani AS, Harding TC et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 2005; 65: 6901-6909.
49. Mandriota SJ, Jussila L, Jeltsch M et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 672-682.
50. Schoppmarm SF, Birner P, Stockl J et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161: 947-956.
51. Dadras SS, Paul T, Bertoncini J et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003; 162: 1951-1960.
52. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med 1999; 5: 292-297.
53. Fraunfelder FW. Pegaptanib for wet macular degeneration. Drugs Today (Barc) 2005; 41: 703-709.
54. Annex BH, Simons M. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res 2005; 65: 649-655.
55. Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOP-CARE-AMI Trial. J Am Coll Cardiol 2004; 44:1690-1699.
56. Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2005; 17: 293-298.
57. Ranieri G, Ria R, Roccaro AM, Vacca A, Ribatti D. Development of vasculature targeting strategies for the treatment of chronic inflammatory diseases. $urr Drug Targets Inflamm Allergy 2005; 4: 13-22.